Sensex Ends 760 Points Lower; IT & Realty Sector Tank Over 3%

Thu, 11 Oct Closing

   Previous Close   

   Pre-Open   

   09:30 am   

   12:30 pm   

Indian share markets ended over 2% lower today following a sharp selloff in the global markets. At the closing bell, BSE Sensex ended down by 760 points, while, NSE Nifty ended down by 225 points.

Except oil & gas stocks, all sectoral indices ended the day in red with realty sector, IT sector and metal sector plunging over 3%.

Globally, Asian stock markets finished sharply lower today with shares in China leading the region. The Shanghai Composite ended down 5.2% while Japan's Nikkei 225 was off 3.9% and Hong Kong's Hang Seng was lower by 3.6%. European markets are sharply lower today with shares in London off the most. The FTSE 100 is down 1.8% while France's CAC 40 is off 1.4% and Germany's DAX is lower by 1.3%.

The rupee was trading at Rs 74.14 against the in the afternoon session.

The Indian rupee today rebounded from its fresh all-time low after crude oil prices and the US dollar fell.

In the afternoon session, the rupee was trading at 74.16 a dollar, up 0.08% from its Wednesday's close of 74.22. In the morning trade, the rupee opened at 74.31 and touched a fresh low of 74.46 a dollar, tracking sell-off in the global markets.

Strong demand for the American currency from importers amid unabated foreign fund outflows and sharp losses in the Indian share markets hurt the sentiment. Concerns of fears of rising fiscal deficit also weighed on the domestic currency.

Meanwhile, the 10-year gilt yield stood at 8.01% from its previous close of 8.031%. Note that, Bond yields and prices move in opposite directions.

Further, oil prices fell to two-week lows today as it extended big losses from the previous session amid a rout in global stock markets, with prices also hit by an industry report showing US crude inventories rose more than expected.

Almost every time, a rise or fall in the stock markets is invariably linked to crude oil prices.

Are Stock Market Returns Really Linked to Crude Oil Prices?

Logically, it seems right too. Rise in crude oil increases input costs for dependent firms. It also means rising inflation. Rising inflation means rising interest rates.

It also puts pressure on the government to cut excise duty, thereby impacting its revenues. We have already seen that happening. After all, there is an election year coming up.

But has it really affected the stock markets? Here's what Girish Shetty thinks:

• "In the short-term: Yes.
  
  But in the long run, as we can see, Sensex returns have been independent of crude oil prices or even positively co-related!
  
  Crude oil prices doubled from US$ 41 in December 2008 to US$84 in April 2010. In the same time, Sensex also doubled from 8,800 levels to 17,600 levels.
  
  So, please don't fret unnecessarily about crude oil.
  
  Check if your business has a moat that helps it pass on input price increases to its customers. In the long run, they will survive and also gain market share from those that can't pass on prices. Short term pessimism due to rising crude oil prices provides a buying opportunity in these stocks.

As per him, focusing on quality stocks rather than crude oil will matter more in the long run.

Moving on to the news from pharma sector. As per an article in a leading financial daily, Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin Oral Suspension 100 mg /5 mL and 200 mg/5 mL.

Azithromycin oral suspension is a generic version of Pfizer Inc's Zithromax oral suspension. The product will be launched in November 2018.

The drug is indicated for the treatment of patients with mild to moderate infections. According to IQVIA, the approved product has an estimated market size of US$71 million for the twelve months ending August 2018.

Reportedly, this is the 125th ANDA (including 11 tentative approvals) to be approved out of Unit III formulation facility in Hyderabad used for manufacturing oral products.

Aurobindo now has a total of 386 ANDA approvals (357 Final approvals including 19 from Aurolife Pharma LLC and 29 tentative approvals) from USFDA.

Aurobindo Pharma share price ended the day down by 3.7%.

To know more about the company, you can access to Aurobindo Pharma's Q1FY19 result analysis and Aurobindo Pharma FY18 annual report analysis on our website.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers